The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

April 5, 2021 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with active psoriatic arthritis (PsA) treated with secukinumab show improvements in all disease manifestations and quality-of-life domains established by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT).1 These findings came from a study by Orbai et al., which examined how PsA patients respond to secukinumab.

You Might Also Like
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Secukinumab Effective for Psoriatic Arthritis
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
Also By This Author
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Previous randomized studies showed the safety and efficacy of secukinumab for patients with PsA, but all used the traditional measure of efficacy based solely on the ACR response criteria. In this study, investigators pooled this evidence in a post hoc analysis to gather more information on the efficacy of secukinumab in specific, individual disease activity core domains for PsA, including musculoskeletal disease activity (i.e., arthritis, enthesitis, dactylitis and spine symptoms), skin disease activity (i.e., psoriasis and nail psoriasis), pain, patient global assessment, physical function, fatigue, health-related quality of life and systemic inflammation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Instead of reporting on ACR20 as the efficacy outcome reported in the primary analysis of each individual trial, we looked individually at those dimensions of PsA representing disease resolution,” says lead author Ana-Maria Orbai, MD, MHS, assistant professor of medicine and director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore.

Post hoc Analysis of Pooled Data
In the study, Orbai et al. pooled data from four on-label phase 3 clinical trials—FUTURE 2, 3, 4 and 5—that demonstrated the efficacy of secukinumab for PsA at approved doses (see Table 1, below). All four of the trials had a loading dose arm of 150 mg of subcutaneous secukinumab, while three of the trials (FUTURE 2, 3 and 5) included a loading dose arm of 300 mg of subcutaneous secukinumab and two trials (FUTURE 4 and 5) had a no-loading dose arm in which patients received 150 mg of secukinumab. Patients were pooled together from these trials based on treatment dose and delivery.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Two thousand forty-nine patients were included in the post hoc analysis. Of these, 461 patients received 300 mg of secukinumab and 572 received 150 mg of secukinumab (each group received treatment at weeks 1, 2, 3 and 4, followed by treatment every four weeks after the initial baseline loading dose). Three hundred and thirty-five received 150 mg of secukinumab every four weeks without a baseline loading dose. A total of 681 patients received placebo. All patients were treated for 16 weeks.

The study included patients who were biologic naive and those who had an inadequate response to tumor necrosis factor inhibitors. Patients in the latter group made up 31.5% of those who received 300 mg of secukinumab, 30.2% of those who received 150 mg of secukinumab, 27.2% of those who received 150 mg of secukinumab with no loading dose at baseline, and 30% of those who received placebo.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: GRAPPA-OMERACT, PsA Resource Center, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Secukinumab Effective for Psoriatic Arthritis
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)